Oral Medications in Vitiligo

  • Koushik Lahiri
  • Samujjala Deb


  • Many treatment modalities have been tried in vitiligo which includes medical and surgical modalities.

  • Medical treatments can include both topical and systemic therapies.

  • Since the etiopathogenesis of vitiligo is complex and not yet fully understood, treatments are often used in conjunction to get the best possible therapeutic benefit.

  • Vitiligo is being increasingly identified as a systemic disease and thus oral medications continue to play an important role in its treatment.


Folic Acid Lipoic Acid Vitiligo Patient Oral Zinc Acneiform Eruption 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Lahiri K. Evolution and evaluation of autologous mini punch grafting in vitiligo. Indian J Dermatol. 2009;54:159–67.CrossRefPubMedPubMedCentralGoogle Scholar
  2. 2.
    Ongenae K, Van Geel N, Naeyaert JM. Evidence for an autoimmune pathogenesis of vitiligo. Pigment Cell Res. 2003;16(2):90–100.CrossRefPubMedGoogle Scholar
  3. 3.
    Lotti T, Gori A, Zanieri F, Colucci R, Moretti S. Vitiligo: new and emerging treatments. Dermatol Ther. 2008;21(2):110–7.CrossRefPubMedGoogle Scholar
  4. 4.
    Szczurko O, Boon HS. A systematic review of natural health product treatment for vitiligo. BMC Dermatol. 2008;8:2.CrossRefPubMedPubMedCentralGoogle Scholar
  5. 5.
    Handa S, Kaur I. Vitiligo: clinical findings in 1436 patients. J Dermatol. 1999;26:653–7.CrossRefPubMedGoogle Scholar
  6. 6.
    Kent G, Al-abadie M. Factors affecting responses on dermatology life quality index among vitiligo sufferers. Clin Exp Dermatol. 1996;21:330–3.CrossRefPubMedGoogle Scholar
  7. 7.
    Parsad D, Pandhi R, Dogra S, Kanwar AJ, Kumar B. Dermatology life quality index score in vitiligo and its impact on the treatment outcome. Br J Dermatol. 2003;148:373–4.CrossRefPubMedGoogle Scholar
  8. 8.
    Parsad D, Gupta S. Standard guidelines of care for vitiligo surgery. Indian J Dermatol Venereol Leprol. 2008;74(S1):37–45.Google Scholar
  9. 9.
    Ismail SA, Sayed DS, Abdelghani LN. Vitiligo management strategy in Jeddah, Saudi Arabia as reported by dermatologists and experienced by patients. J Dermatol Treat. 2014;25:205–11.CrossRefGoogle Scholar
  10. 10.
    Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview part II: treatment options and approach to treatment. J Am Acad Dermatol. 2011;65(3):493–514.CrossRefPubMedGoogle Scholar
  11. 11.
    Felsten LM, Alikhan A, Petronic-Rosic V. Vitiligo: a comprehensive overview: part I. Introduction, epidemiology, quality of life, diagnosis, differential diagnosis, associations, histopathology, etiology, and work-up. J Am Acad Dermatol. 2011;65(3):473–91.CrossRefPubMedGoogle Scholar
  12. 12.
    Taieb A, Alomar A, Bohm M, Dell’anna ML, De Pase A, Eleftheriadou V, et al. Guidelines for the management of vitiligo: the European Dermatology Forum consensus. Br J Dermatol. 2013;168(1):5–19.CrossRefPubMedGoogle Scholar
  13. 13.
    Ezzedine K, Lim HW, Suzuki T, Katayama I, Hamzavi I, Lan CC, et al. Revised classification/nomenclature of vitiligo and related issues: the Vitiligo Global Issues Consensus Conference. Pigm Cell Melanoma Res. 2012;25(3):E1–13.CrossRefGoogle Scholar
  14. 14.
    Lotti T. Vitiligo: problems and solutions. Int J Immunopath Pharmacol Dermatol. 2002;13:325–8.Google Scholar
  15. 15.
    Taieb A, Piccardo M. Clinical practice: vitiligo. N Engl J Med. 2009;360:160–9.CrossRefPubMedGoogle Scholar
  16. 16.
    Buggiani G, Tsampau D, Hercogovà J, Rossi R, Brazzini B, Lotti T. Clinical efficacy of a novel topical formulation for vitiligo: compared evaluation of different treatment modalities in 149 patients. Dermatol Ther. 2012;25(5):472–6.CrossRefPubMedGoogle Scholar
  17. 17.
    Kathuria S, Khaitan BK, Ramam M, Sharma VK. Segmental vitiligo: a randomized controlled trial to evaluate efficacy and safety of 0.1% tacrolimus ointment vs 0.05% fluticasone propionate cream. Indian J Dermatol Venereol Leprol. 2012;78(1):68–73.CrossRefPubMedGoogle Scholar
  18. 18.
    Lahiri K. Stability in vitiligo? What’s that? J Cutan Aesthet Surg. 2009;2(1):38–40.CrossRefPubMedPubMedCentralGoogle Scholar
  19. 19.
    Lahiri K, Malakar S. The concept of stability of vitiligo: a reappraisal. Indian J Dermatol. 2012;57:83–9.CrossRefPubMedPubMedCentralGoogle Scholar
  20. 20.
    Brosthoff H, Brosthoff J. Vitiligo and steroids. Lancet. 1978;2:688.CrossRefGoogle Scholar
  21. 21.
    Thomas PS. Prednisolone causing amelioration of both vitiligo and chronic active hepatitis. Br J Hosp Med. 1978;38:464.Google Scholar
  22. 22.
    Pasricha JS, Seetharam KA, Dashore A. Evaluation of five different regimens for the treatment of vitiligo. Indian J Dermatol Venereol Leprol. 1989;55:18–21.PubMedGoogle Scholar
  23. 23.
    Gupta R. Causes of vitiligo. In: Gupta R, editor. Leucoderma (vitiligo). 1st ed. New Delhi: Atlantic Publishers and Distributors; 2007. p. 20–40.Google Scholar
  24. 24.
    Rath N, Kar HK, Sabhnani S. An open labeled, comparative clinical study on efficacy and tolerability of oral minipulse of steroid (OMP) alone, OMP with PUVA and broad/narrowband UVB phototherapy in progressive vitiligo. Indian J Dermatol Venereol Leprol. 2008;74:357–60.CrossRefPubMedGoogle Scholar
  25. 25.
    Gupta RR. Modified oral mini pulse steroid therapy in unstable vitiligo: a novel once a week regimen. Presented at 29th Annual Conference of IADVL; 2001. Unpublished.Google Scholar
  26. 26.
    Imran M. Childhood vitiligo: response to methylprednisolone OMP therapy and topical fluticasone preparation. Indian J Dermatol. 2010;54:124–7.Google Scholar
  27. 27.
    Pasricha JS, Khaitan BK. Oral minipulse therapy with betamethasone in vitiligo patients having extensive or fast spreading disease. Int J Dermatol. 2001;44:814–7.Google Scholar
  28. 28.
    Radakovik Fijan S, Furnissn-Friedl AM, Tanew A, Honigsman H. Oral dexamethasone pulse treatment for vitiligo. J Am Acad Dermatol. 2001;44:814–7.CrossRefGoogle Scholar
  29. 29.
    Seiter S, Ugurel S, Tilgen W, Reinhold U. Use of high-dose methylprednisolone pulse therapy in patients with progressive and stable vitiligo. Int J Dermatol. 2000;39:624–7.CrossRefPubMedGoogle Scholar
  30. 30.
    Nagata Y, Tanemura A, Ono E, Tanaka A, Kato K, Yamada M, Katayama I. Preliminary colorimetric assessment of progressive nonsegmental vitiligo under short-term intravenous methylprednisolone pulse therapy. J Cosm Dermatol Sci Appl. 2014;4:135–40.Google Scholar
  31. 31.
    Lee Y, Seo YJ, Lee JH, Park JK. High-dose prednisolone and psoralen ultraviolet a combination therapy in 36 patients with vitiligo. Clin Exp Dermatol. 2007;32:499–501.CrossRefPubMedGoogle Scholar
  32. 32.
    Radmaneesh M, Saedi K. The efficacy of combined PUVA and low dose azathioprine for early and enhanced repigmentation in vitiligo patients. J Dermatol Treat. 2006;17:151–3.CrossRefGoogle Scholar
  33. 33.
    Sandra A, Pai S, Shenoi SD. Unstable vitiligo responding to methotrexate. Indian J Dermatol Venereol Leprol. 1998;64:309.PubMedGoogle Scholar
  34. 34.
    Gokhale BB. Cyclophosphamide and vitiligo. Int J Dermatol. 1979;18:92.PubMedGoogle Scholar
  35. 35.
    Gupta AK, Ellis CN, Nickoloff BJ, Nickoloff BJ, Goldfarb MT, Ho VC, et al. Oral cyclosporine in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126:339–50.CrossRefPubMedGoogle Scholar
  36. 36.
    Rigopoulos D, Gregorious S, Larios G, Larios G, Moustou E, Belayeva-Karatza E, Kalogeromitros D. Etanercept in the treatment of vitiligo. Dermatol. 2007;215:84–5.CrossRefGoogle Scholar
  37. 37.
    Smith DI, Heffernan MP. Vitiligo after the resolution of psoriatic plaques during treatment with adalimumab. J Am Acad Dermatol. 2008;58:S50–1.CrossRefPubMedGoogle Scholar
  38. 38.
    Ramı’rez-Herna’ndez M, Marras C, Martı’nez-Escribano JA. Infliximab- induced vitiligo. Dermatol. 2005;210:79–80.CrossRefGoogle Scholar
  39. 39.
    McKenna WB. Ammi majus Linn in the treatment of vitiligo. Scott Med J. 1957;2:69–70.CrossRefPubMedGoogle Scholar
  40. 40.
    Benedetto AV. The psoralens. A historical perspective. Cutis. 1977;20:469–71.PubMedGoogle Scholar
  41. 41.
    Fowlks WL. The chemistry of the psoralens. J Invest Dermatol. 1959;32:249–54.CrossRefPubMedGoogle Scholar
  42. 42.
    El Mofty AM. A preliminary clinical report on the treatment of leucoderma with Ammi majus Linn. J Egypt Med Assoc. 1948;31:651–65.Google Scholar
  43. 43.
    Pathak MA, Fellman JH. Activating and fluorescent wave-lengths of furocoumarins: psoralens. Nature. 1960;185:382–3.CrossRefPubMedGoogle Scholar
  44. 44.
    Buck HW, Magnus IA, Porter AD. The action spectrum of 8-methoxypsoralen for erythema in human skin: preliminary studies with a monochromator. Br J Dermatol. 1960;72:249–55.CrossRefPubMedGoogle Scholar
  45. 45.
    Fulton Jr JE, Leyden J, Papa C. Treatment of vitiligo with topical methoxsalen and blacklite. Arch Dermatol. 1969;100:224–9.CrossRefPubMedGoogle Scholar
  46. 46.
    Bouattour H, Chaabouni M. Comparative analytical study of the effects of psoralens in vitiligo (findings in 70 patients) (author’s transl). Ann Dermatol Venereol. 1978;105:507–10.PubMedGoogle Scholar
  47. 47.
    Sharma VK, Jerajani HR, Srinivas HR, Kanwar AJ, Premalatha S, Sengupta SR, et al. Guidelines for medical management of vitiligo. In: Sharma VK, editor. IADVL therapeutic guidelines: guidelines for vitiligo, Stevens Johnson Syndrome-Toxic Epidermal Necrolysis and psoriasis. 1st ed. New Delhi: IADVL; 2009. p. 1–72.Google Scholar
  48. 48.
    Morison WL, Baugham RD, Day RM, Forbes PD, Hoenigsmann H, Krueger GG, et al. Consensus workshop on the toxic effects of long-term PUVA therapy. Arch Dermatol. 1998;134:595–8.PubMedGoogle Scholar
  49. 49.
    Grimes PE, Minus HR, Chakrabarti SG, Enterline J, Halder R, Gough JE, et al. Determination of optimal topical photochemotherapy for vitiligo. J Am Acad Dermatol. 1982;7:771–8.CrossRefPubMedGoogle Scholar
  50. 50.
    El Mofty M, Mostafa W, Esmat S, Youssef R, Azzam O, Hunter N, et al. Narrow band ultraviolet B 311 nm in the treatment of vitiligo: two right-left comparison studies. Photodermatol Photoimmunol Photomed. 2006;22:6–11.CrossRefPubMedGoogle Scholar
  51. 51.
    Bhatnagar A, Kanwar AJ, Parsad D, De D. Comparison of systemic PUVA and NB-UVB in the treatment of vitiligo: an open prospective study. J Eur Acad Dermatol Venereol. 2007;21:638–42.CrossRefPubMedGoogle Scholar
  52. 52.
    Westerhof W, Nieuweboer-Krobotova L. Treatment of vitiligo with UV-B radiation vs topical psoralen plus UV-A. Arch Dermatol. 1997;133:1525–8.CrossRefPubMedGoogle Scholar
  53. 53.
    Yones SS, Palmer RA, Garibaldinos TM, Hawk JL. Randomized double-blind trial of treatment of vitiligo: efficacy of psoralen–UV-A therapy vs narrowband–UV-B therapy. Arch Dermatol. 2007;143:578–84.CrossRefPubMedGoogle Scholar
  54. 54.
    Kwok YK, Anstey AV, Hawk JL. Psoralen photochemotherapy (PUVA) is only moderately effective in widespread vitiligo: a 10-year retrospective study. Clin Exp Dermatol. 2002;27:104–10.CrossRefPubMedGoogle Scholar
  55. 55.
    British Photodermatology Group. An appraisal guideline for PUVA. Br J Dermatol. 1994;130:246–55.CrossRefGoogle Scholar
  56. 56.
    Ortel B, Tanew A, Honigsmann H. Treatment of vitiligo with khellin and ultraviolet A. J Am Acad Dermatol. 1988;18:693–701.CrossRefPubMedGoogle Scholar
  57. 57.
    Orecchia G, Perfetti L. Photochemotherapy with topical khellin and sunlight in vitiligo. Dermatol. 1992;184:120–3.CrossRefGoogle Scholar
  58. 58.
    Dell’Anna ML, Picardo M. A review and a new hypothesis for non-immunological pathogenetic mechanisms in vitiligo. Pigm Cell Res. 2006;19:406–11.CrossRefGoogle Scholar
  59. 59.
    Picardo M, Dell’Anna ML. Vitamins and antioxidants: topical and systemic. In: Picardo M, Taieb A, editors. Vitiligo. Berlin: Springer; 2010. p. 369–74.CrossRefGoogle Scholar
  60. 60.
    Akyol M, Celik VK, Ozcelik S, Polat M, Marufihah M, Atalay A. The effects of vitamin E on the skin lipid peroxidation and the clinical improvement in vitiligo patients treated with PUVA. Eur J Dermatol. 2002;12:24–6.PubMedGoogle Scholar
  61. 61.
    Dell’Anna ML, Mastrofrancesco A, Sala R, Venturini M, Ottaviani M, Vidolin AP, et al. Antioxidants and narrow band-UVB in the treatment of vitiligo: a double-blind placebo controlled trial. Clin Exp Dermatol. 2007;32:631–6.CrossRefPubMedGoogle Scholar
  62. 62.
    Middelkamp-Hup MA, Bos JD, Riuz-Diaz F, Gonzalez S, Westerhof W. Treatment of vitiligo vulgaris with narrow band UVB and oral Polypodium leucotomos extract: a randomized double-blind placebo controlled study. J Eur Acad Dermatol Venereol. 2007;21:942–50.CrossRefPubMedGoogle Scholar
  63. 63.
    Parsad D, Pandhi R, Juneja A. Effectiveness of oral Ginkgo biloba in treating limited, slowly spreading vitiligo. Clin Exp Dermatol. 2002;28:285–7.CrossRefGoogle Scholar
  64. 64.
    Szczurko O, Shear N, Taddio A, Boon H. Ginkgo biloba for the treatment of vitiligo vulgaris: an open label pilot clinical trial. BMC Complement Altern Med. 2011;11:21.CrossRefPubMedPubMedCentralGoogle Scholar
  65. 65.
    Trompezinski S, Bonneville M, Pernet I, Denis A, Schmitt D, Viac J. Gingko biloba extract reduces VEGF and CXCL-8/IL-8 levels in keratinocytes with cumulative effect with epigallocatechin-3-gallate. Arch Dermatol Res. 2010;302(3):183–9.CrossRefPubMedGoogle Scholar
  66. 66.
    Bent S, Goldberg H, Padula A, Avins AL. Spontaneous bleeding associated with Ginkgo biloba: a case report and systematic review of the literature: a case report and systematic review of the literature. J Gen Intern Med. 2005;20(7):657–61.CrossRefPubMedPubMedCentralGoogle Scholar
  67. 67.
    Cohen BE, Elbuluk N, Mu EW, Orlow SJ. Alternative systemic treatments for vitiligo: a review. Am J Clin Dermatol. 2015;16(6):463–74.Google Scholar
  68. 68.
    Harris JE, Harris TH, Weninger W, Wherry EJ, Hunter CA, Turka LA. A mouse model of vitiligo with focused epidermal depigmentation requires IFN-gamma for autoreactive CD8(+) T-cell accumulation in the skin. J Invest Dermatol. 2012;132(7):1869–76.CrossRefPubMedPubMedCentralGoogle Scholar
  69. 69.
    Spritz RA. Recent progress in the genetics of generalized vitiligo. J Genet Genomics. 2011;38(7):271–8.CrossRefPubMedPubMedCentralGoogle Scholar
  70. 70.
    Spritz RA. Shared genetic relationships underlying generalized vitiligo and autoimmune thyroid disease. Thyroid. 2010;20(7):745–54.CrossRefPubMedPubMedCentralGoogle Scholar
  71. 71.
    Egli F, Walter R. Images in clinical medicine. Vitiligo and pernicious anemia. N Engl J Med. 2004;350(26):2698.CrossRefPubMedGoogle Scholar
  72. 72.
    Schallreuter KU, Chavan B, Rokos H, Hibberts N, Panske A, Wood JM. Decreased phenylalanine uptake and turnover in patients with vitiligo. Mol Genet Metab. 2005;86(S1):S27–33.CrossRefPubMedGoogle Scholar
  73. 73.
    Schallreuter KU, Zschiesche M, Moore J, Panske A, Hibberts NA, Herrmann FH, et al. In vivo evidence for compromised phenylalanine metabolism in vitiligo. Biochem Biophys Res Commun. 1998;243(2):395–9.CrossRefPubMedGoogle Scholar
  74. 74.
    Antoniou C, Schulpis H, Michas T, Katsambas A, Frajis N, Tsagaraki S, et al. Vitiligo therapy with oral and topical phenylalanine with UVA exposure. Int J Dermatol. 1989;28(8):545–7.CrossRefPubMedGoogle Scholar
  75. 75.
    Ryan WL, Carver MJ. Inhibition of antibody synthesis by L-phenylalanine. Science. 1964;143(3605):479–80.CrossRefPubMedGoogle Scholar
  76. 76.
    Siddiqui AH, Stolk LM, Bhaggoe R, Hu R, Schutgens RB, Westerhof W. L-phenylalanine and UVA irradiation in the treatment of vitiligo. Dermatol. 1994;188(3):215–8.CrossRefGoogle Scholar
  77. 77.
    Cormane RH, Siddiqui AH, Westerhof W, Schutgens RB. Phenylalanine and UVA light for the treatment of vitiligo. Arch Dermatol Res. 1985;277(2):126–30.CrossRefPubMedGoogle Scholar
  78. 78.
    Thiele B, Steigleder GK. Repigmentation treatment of vitiligo with L-phenylalanine and UVA irradiation [in German]. Z Hautkr. 1987;62(7):519–23.PubMedGoogle Scholar
  79. 79.
    Karadag AS, Tutal E, Ertugrul DT, Akin KO, Bilgili SG. Serum holotranscobalamine, vitamin B12, folic acid and homocysteine levels in patients with vitiligo. Clin Exp Dermatol. 2012;37(1):62–4.CrossRefPubMedGoogle Scholar
  80. 80.
    Shaker OG, El-Tahlawi SM. Is there a relationship between homocysteine and vitiligo? A pilot study. Br J Dermatol. 2008;159(3):720–4.PubMedGoogle Scholar
  81. 81.
    Howitz J, Schwartz M. Vitiligo, achlorhydria, and pernicious anemia. Lancet. 1971;1(7713):1331–4.CrossRefPubMedGoogle Scholar
  82. 82.
    Sabry HHSJ, Hashim HM. Serum levels of homocysteine, vitamin B12, and folic acid in vitiligo. Egypt J Dermatol Venereol. 2014;34:65–9.CrossRefGoogle Scholar
  83. 83.
    Montes LF, Diaz ML, Lajous J, Garcia NJ. Folic acid and vitamin B12 in vitiligo: a nutritional approach. Cutis. 1992;50(1):39–42.PubMedGoogle Scholar
  84. 84.
    Juhlin L, Olsson MJ. Improvement of vitiligo after oral treatment with vitamin B12 and folic acid and the importance of sun exposure. Acta Derm Venereol. 1997;77(6):460–2.PubMedGoogle Scholar
  85. 85.
    Tjioe M, Gerritsen MJ, Juhlin L, van de Kerkhof PC. Treatment of vitiligo vulgaris with narrow band UVB (311 nm) for one year and the effect of addition of folic acid and vitamin B12. Acta Derm Venereol. 2002;82(5):369–72.CrossRefPubMedGoogle Scholar
  86. 86.
    Singh S, Singh U, Pandey SS. Increased level of serum homocysteine in vitiligo. J Clin Lab Anal. 2011;25(2):110–2.CrossRefPubMedGoogle Scholar
  87. 87.
    Shameer P, Prasad PV, Kaviarasan PK. Serum zinc level in vitiligo: a case control study. Indian J Dermatol Venereol Leprol. 2005;71(3):206–7.CrossRefPubMedGoogle Scholar
  88. 88.
    Bagherani N, Yaghoobi R, Omidian M. Hypothesis: zinc can be effective in treatment of vitiligo. Indian J Dermatol. 2011;56(5):480–4.CrossRefPubMedPubMedCentralGoogle Scholar
  89. 89.
    Yaghoobi R, Omidian M, Bagherani N. Comparison of therapeutic efficacy of topical corticosteroid and oral zinc sulfate-topical corticosteroid combination in the treatment of vitiligo patients: a clinical trial. BMC Dermatol. 2011;11:7.CrossRefPubMedPubMedCentralGoogle Scholar
  90. 90.
    Parsad D, Kanwar AJ. Oral minocycline in the treatment of vitiligo—a preliminary study. Dermatol Ther. 2010;23:305–7.CrossRefPubMedGoogle Scholar
  91. 91.
    Silverberg JI, Silverberg AI, Malka E, Silverberg NB. A pilot study assessing the role of 25 hydroxy vitamin D levels in patients with vitiligo vulgaris. J Am Acad Dermatol. 2010;62(6):937–41.CrossRefPubMedGoogle Scholar
  92. 92.
    Sehrawat M, Arora TC, Chauhan A, Kar HK, Poonia A, Jairath V. Correlation of vitamin D levels with pigmentation in vitiligo patients treated with NBUVB therapy. ISRN Dermatol. 2014;3:1–6.CrossRefGoogle Scholar
  93. 93.
    Finamor DC, Sinigaglia-Coimbra R, Neves LC, Gutierrez M, Silva JJ, Torres LD, et al. A pilot study assessing the effect of prolonged administration of high daily doses of vitamin D on the clinical course of vitiligo and psoriasis. Dermato Endocrinol. 2013;5:222–34.CrossRefGoogle Scholar
  94. 94.
    Batchelor JM, Tan W, Tour S, Yong A, Montgomery AA, Thomas KS. Validation of the vitiligo noticeability scale: a patient-reported outcome measure of vitiligo treatment success. Br J Dermatol. 2016;174(2):386–94.Google Scholar
  95. 95.
    Lahiri K. Punch grafting in vitiligo. Indian J Dermatol Venereol Leprol. 1998;64:310–1.PubMedGoogle Scholar
  96. 96.
    Lahiri K, Malakar S, Sarma N, Banerjee U. Inducing repigmentation by regrafting and phototherapy (311 nm) in punch grafting failure cases of lip vitiligo: a pilot study. Indian J Dermatol Venereol Leprol. 2004;70:156–8.PubMedGoogle Scholar

Copyright information

© Springer India 2017

Authors and Affiliations

  1. 1.Apollo Gleneagles Hospitals, WIZDERMKolkataIndia
  2. 2.St. John’s Medical College & HospitalBangaloreIndia

Personalised recommendations